Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Neos Therapeutics, Inc. (NEOS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...|
Docs:
|
"Fifth Amended and Restated Certificate of Incorporation of Neos Therapeutics, Inc",
"Second Amended and Restated Bylaws of Neos Therapeutics, Inc",
"Consent, Waiver and Sixth Amendment to Facility Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, Deerfield Private Design Fund III L.P., Deerfield Partners, L.P. and Deerfield Mgmt, L.P.",
"Consent, Waiver and Amendment No. 1 to Loan and Security Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, and Encina Business Credit, LLC",
"Aytu BioScience Announces Close of Merger with Neos Therapeutics" |
|
| 02/08/2021 |
8-K
| Quarterly results |
| 01/11/2021 |
8-K
| Quarterly results |
| 12/30/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/11/2020 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Agreement and Plan of Merger, dated as of December 10, by and among Neos, Therapeutics, Inc., Aytu BioScience, Inc. and Neutron Acquisition Sub, Inc",
"VOTING AND Support AGREEMENT for parent Securityholders THIS VOTING AND SUPPORT AGREEMENT is made and entered into as of December [●], 2020, by and among Neos Therapeutics, Inc., a Delaware corporation , and the stockholders of Aytu Bioscience Inc., a Delaware corporation listed on Schedule A hereto . Capitalized terms used but not defined herein are used as they are defined in the Merger Agreement . RECITALS: A. Securityholder owns beneficially and of record the shares of capital stock of Parent as set forth opposite Securityholder’ s name on Schedule A hereto . B. Upon the satisfaction or waiver of the terms and conditions of the Agreement and Plan of Merger by and among Parent, Merger Sub and the Company, dated as of the date hereof , Merger Sub will be merged with and into the Co...",
"VOTING AND Support AGREEMENT for company securityholders THIS VOTING AND SUPPORT AGREEMENT is made and entered into as of December [●], 2020, by and among Aytu Bioscience Inc., a Delaware corporation , Neutron Acquisition Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent and the stockholders of Neos Therapeutics, Inc., a Delaware corporation listed on Schedule A hereto . Capitalized terms used but not defined herein are used as they are defined in the Merger Agreement . RECITALS: A. Securityholder owns beneficially and of record the shares of capital stock of the Company as set forth opposite Securityholder’ s name on Schedule A hereto . B. Upon the satisfaction or waiver of the terms and conditions of the Agreement and Plan of Merger by and among Parent, Merg...",
"Letter re: Acquisition of Neos Therapeutics, Inc.",
"UNSECURED CONVERTIBLE PROMISSORY NOTE",
"Execution Version",
"LIMITED WAIVER",
"Execution Version",
"Execution Version LIMITED WAIVER TO LOAN AND SECURITY AGREEMENT",
"0.4 M 0.3 M 0.6 M 0.1 M" |
|
| 12/10/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue 1 Specialty Pharmaceutical Company - Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 - Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’ s footprint in pediatrics and expanding its presence in adjacent specialty care segments - Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’ s product portfolio of best-in-class prescription therapeutics and consumer health products - Companies to host joint conference call today at 8:30 am ET ENGLEWOOD, CO and GRAND PRAIRIE, TX / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. , a specia..." |
|
| 11/09/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 06/19/2020 |
8-K
| Quarterly results |
| 06/11/2020 |
8-K
| Director compensation was amended/approved |
| 05/11/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 04/23/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 04/09/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 03/30/2020 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 03/13/2020 |
8-K
| Quarterly results |
| 11/08/2019 |
8-K
| Quarterly results |
| 10/03/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 06/18/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 03/14/2019 |
8-K
| Quarterly results |
| 01/30/2019 |
8-K
| Quarterly results |
| 12/26/2018 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 12/11/2018 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/30/2018 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 11/09/2018 |
8-K
| Quarterly results |
| 11/08/2018 |
8-K
| Other Events |
| 11/06/2018 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 11/05/2018 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obl...|
Docs:
|
"Form of Senior Secured Convertible Promissory Note",
"Second Amendment to Facility Agreement, by and among Neos Therapeutics, Inc., Deerfield Private Design Fund III, L.P. and Deerfield Special Situation Fund, L.P. (including schedules and exhibits thereto)",
"Registration Rights Agreement, by and among Neos Therapeutics, Inc., Deerfield Private Design Fund III, L.P. and Deerfield Special Situation Fund, L.P" |
|
| 10/24/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 08/08/2018 |
8-K
| Quarterly results |
| 06/27/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/22/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
|
|
|